Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma?

Peter MacCallum Cancer Centre0 个研究点目标入组 20 人开始时间: 2014年5月20日最近更新: 2024年4月22日

适应症

试验速览

暂无简介。

•1. Primary choroidal melanoma (small and medium sized)
•- A clinical diagnosis of CM made by a suitably trained ophthalmologist is mandatory
•- Features that define CM and must be present are a choroidal mass that is pigmented or hypopigmented AND EITHER:
•a) Tumour height measured on beta ultrasound to be 2.5mm or greater OR
•b) Documented growth of a lesion <2.5mm in height
•2. Tumour height to 8mm or less
•3. Tumour basal diameter 16mm or less
•4. Visual acuity better than 6/60 ( or 0.1)
•5. No evidence of metastatic disease on liver ultrasound
•6. Age 70 or less
•7. An ECOG performance status score of 0 - 2
•8. Participants capable of childbearing are using adequate contraception
•9. Available for follow up
•10. Has provided written Informed Consent for participation in this trial

•1. Tumour involving the iris or ciliary body
•2. Cytopathologic diagnosis is not uveal melanoma
•3. Previous treatment to the affected eye with radiation, laser or thermotherapy
•4. Non-malignant disease of the affected eye (that already has or could affect vision)
•5. Known to have diabetes mellitus
•6. Prior diagnosis of cancer that was:
•- more than 5 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence is greater than 10%
•- within 5 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix
•7. Patients with clinical evidence of metastatic disease.
•8. Women who are pregnant
•9. Unable to give informed consent

发起方

Peter MacCallum Cancer Centre